Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock)
US ˙ NYSE ˙ US8816242098

SecurityTEVA / Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock)
InstitutionDRW Securities, LLC
Latest Disclosed Ownership25,671 shares
Latest Disclosed Value $ 773,210
DRW Securities, LLC reports 105.35% increase in ownership of TEVA / Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock)

On May 13, 2026 - DRW Securities, LLC filed a 13F-HR form disclosing ownership of 25,671 shares of Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock) (US:TEVA) valued at $773,211 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 12,501 shares of Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock). This represents a change in shares of 105.35% during the quarter. The current value of the position is $842,779 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F TEVA PHARMAC.IND.ADR COM 881624209 25,671 13,170 105.35 773 98.21 0.0107
2026-02-12 2025-12-31 13F TEVA PHARMAC.IND.ADR COM 881624209 12,501 -5,103 -28.99 390 9.55 0.0103
2025-11-14 2025-09-30 13F TEVA PHARMAC.IND.ADR COM 881624209 17,604 3,772 27.27 357 54.11 0.0065
2025-08-14 2025-06-30 13F TEVA PHARMAC.IND.ADR COM 881624209 13,832 13,832 232 0.0052
2022-08-11 2022-06-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 0 -18,576 -100.00 0 -100.00
2022-05-12 2022-03-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 18,576 18,576 174 0.0047
2020-11-12 2020-09-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 0 -10,717 -100.00 0 -100.00
2020-08-14 2020-06-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 10,717 0 0.00 132 37.50 0.0062
2020-05-13 2020-03-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 10,717 10,717 96 0.0035
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.